Company profile
Barinthus Biotherapeutics plc, together with its subsidiaries, engages in the research, development, and commercialization of immunotherapies and vaccines in the United States and the United Kingdom. The company develops VTP-1000, an antigen-specific immune tolerance candidate, which is in Phase I clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease; and VTP-300, an immunotherapy, which is in Phase II clinical trial for the treatment of chronic hepatitis
- CEO
- Mr. William James Enright MBA
- Headquarters
- Germantown, MD, United States
- Employees
- 14
- IPO date
- Apr 30, 2021
- Sector
- Healthcare
- Industry
- Biotechnology